Sitemap
Posts by category
- Category: News
- Acuitas Therapeutics and collaborators demonstrate strong protection against P. vivax malaria with mRNA-LNP vaccine
- Acuitas Therapeutics announces oral presentations at the 2025 Alliance for mRNA Medicines’ Annual Meeting
- Acuitas Therapeutics contributes to new insights into broadly neutralizing antibodies induced by COVID-19 mRNA vaccines
- Acuitas Therapeutics’ scientists collaborate with the University of Zurich and the University of Pennsylvania to develop a novel deep learning model for efficient adenine base editing
- Acuitas Therapeutics presents new method for mRNA-LNP production using preformed vesicles at CRS 2025
- Acuitas Therapeutics and researchers at the University of Pennsylvania demonstrate enhanced T cell immunity with IL-12 mRNA-LNP adjuvant
- Acuitas Therapeutics collaborates on mRNA-LNP prime editing study for genetic liver disease
- Malewana et al. (2025) “Nonstabilized SARS-CoV-2 spike mRNA vaccination induces broadly neutralizing antibodies in nonhuman primates” Science Translational Medicine.
- Aunins et al. (2025) “An Il12 mRNA-LNP adjuvant enhances mRNA vaccine–induced CD8 T cell responses” Science Immunology.
- Rothgangl et al. (2025) “Treatment of a metabolic liver disease in mice with a transient prime editing approach” Nature Biomedical Engineering.
- Acuitas Therapeutics showcases collaboration with Children’s Hospital of Philadelphia for personalized CRISPR therapy and new LNP research at ASGCT 2025
- Musunuru et. al (2025) “Patient-specific in vivo gene editing to treat a rare genetic disease” The New England Journal of Medicine.
- Kissling et al. (2025) “Predicting adenine base editing efficiencies in different cellular contexts by deep learning” Genome Biology.
- Acuitas Therapeutics demonstrates enhanced mRNA-LNP activity in cancer and viral vaccine development
- Acuitas to present data on latest LNP safety and activity profiles at ASGCT 2025
- Acuitas awarded as one of Canada’s Most Admired™ Corporate Cultures for 2024
- PUBLICATION ALERT: CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery
- Papp et al. (2025) “CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery” Molecular Therapy.
- PUBLICATION ALERT: Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection
- Broomfield et al. (2025) “Transient inhibition of type I interferon enhances CD8+ T cell stemness and vaccine protection” Journal of Experimental Medicine.
- PUBLICATION ALERT: Monitoring mRNA vaccine antigen expression in vivo using PET/CT
- Blizard et al. (2025) “Monitoring mRNA vaccine antigen expression in vivo using PET/CT” Nature Communications.
- PUBLICATION ALERT: iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA
- Yanik et al. (2025) “iDC-targeting PfCSP mRNA vaccine confers superior protection against Plasmodium compared to conventional mRNA” NPJ Vaccines.
- Acuitas Therapeutics’ Chief Legal Officer Miranda Lam Appointed as King’s Counsel
- Dr. Ghania Chikh Named Senior Director, Vaccine Development at Acuitas Therapeutics
- Acuitas Therapeutics’ President & CEO Named a National Winner in the EY Canadian Entrepreneur of the Year Program
- Category: Presentations
- An Alternative Method to RNA Lipid Nanoparticle Production
- Evolving Lipid Nanoparticles to Optimize Clinical Application of messenger RNA Therapeutics
- Pharmacodynamic Activity, Pharmacokinetics and Tolerability of Lipid Nanoparticle Formulations of mRNA Following Repeated Intravenous Dosing in Monkeys
- Delivery, Potency, and Tolerability of Lipid Nanoparticle Formulations of mRNA in PXB-mice
- Improved T Cell Delivery and Expression of mRNA Using CD8-Targeted Lipid Nanoparticles with Athebody® Designed Ankyrin Repeat Proteins (DARPins)
- Development of LNP for mRNA Cancer Immunotherapy (Presentation)
- Development of LNP for mRNA Cancer Immunotherapy (Poster)
- Identification of Novel Lipids with Improved Activity for Prophylactic Vaccine Development
- Optimizing Ionizable Lipid & LNP Properties to Improve Safety
- mRNA Therapeutics Delivery with Next Generation Ionizable Lipids
- Identification of Novel Lipids With Improved Activity for Prophylactic Vaccine Development
- Category: Publications
- Shuvaev et al. (2025) “Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo” PNAS.
- Surisaeng et al. (2025) “BMP-2 mRNA-transfected BMSCs promote superior calvarial bone regeneration” Scientific Reports.
- Acuitas Therapeutics named one of Canada’s Top Small & Medium Employers of 2025
- Acuitas Therapeutics named one of BC’s Top Employers of 2025
- Tremblay et al. (2025) “A potent epigenetic editor targeting human PCSK9 for durable reduction of low-density lipoprotein cholesterol levels” Nature Medicine.
- PUBLICATION ALERT: High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays
- Imiolek et al. (2025) “High-throughput quantification and characterization of dual payload mRNA/LNP cargo via deformulating size exclusion and ion pairing reversed phase assays” Analytical Chemistry.
- PUBLICATION ALERT: Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles
- Banda et al. (2025) “Restoring hematopoietic stem and progenitor cell function in Fancc−/− mice by in situ delivery of RNA lipid nanoparticles” Molecular Therapy.
- Smith et al. (2024) “Impact of metabolic states on SARS-CoV-2 vaccine responses in mouse models of obesity and diabetes” MDPI.
- Acuitas Scientist Presented at 3rd LNP Immunogenicity & Toxicity Summit
- Abt et al. (2024) “Staggered immunization with mRNA vaccines encoding SARS-CoV-2 polymerase or spike antigens broadens the T cell epitope repertoire” PNAS.
- Acuitas Therapeutics Named One of Canada’s Most Admired™ Corporate Cultures by Waterstone
- Acuitas Therapeutics Honoured With Philanthropic Award
- Acuitas Scientists Highlight Next Generation LNP Technology at International mRNA Health Conference
- Castruccio Castracani et al. (2024) “An erythroid-specific lentiviral vector improves anemia and iron metabolism in a new model of XLSA” Blood.
- Chappell et al. (2024) “Use of HSC targeted LNP to generate a mouse model of lethal α-Thalassemia and treatment via lentiviral gene therapy” Blood.
- Leonard et al. (2024) “Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA” Nature Communications.
- PUBLICATION ALERT: Improved influenza vaccine responses after expression of multiple viral glycoproteins from a single mRNA
- Cohen et al. (2024) “Mosaic sarbecovirus nanoparticles elicit cross-reactive responses in pre-vaccinated animals” Cell.
- Alameh et al. (2024) “A multivalent mRNA-LNP vaccine protects against Clostridioides difficile infection” Science.
- Atochina-Vasserman et al. (2024) “Bivalent norovirus mRNA vaccine elicits cellular and humoral responses protecting human enteroids from GII.4 infection” NPJ Vaccines.
- Kafle et al. (2024) “The roles of CD4+ T cell help, sex, and dose in the induction of protective CD8+ T cells against a lethal poxvirus by mRNA-LNP vaccines” Molecular Therapy Nucleic Acids.
- Kuzmin et al. (2024) “Comparison of uridine and N1-methylpseudouridine mRNA platforms in development of an Andes virus vaccine” Nature Communications.
- Guenaga et al. (2024) “mRNA lipid nanoparticles expressing cell-surface cleavage independent HIV Env trimers elicit autologous tier-2 neutralizing antibodies” Frontiers in Immunology.
- Christopher Sweeney Named Executive Director, Intellectual Property
- England et al. (2024) “Evaluation of mRNA-LNP and adjuvanted protein SARS-CoV-2 vaccines in a maternal antibody mouse model” NPJ Vaccines.
- Smith et al. (2024) “Transient growth factor expression via mRNA in lipid nanoparticles promotes hepatocyte cell therapy in mice” Nature Communications.
- Parhiz et al. (2024) “Physiologically-based modeling of LNP-mediated delivery of mRNA in the vascular system” Molecular Therapy Nucleic Acids.
- Montoya et al. (2024) “mRNA-LNP vaccine-induced CD8+ T-cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies” Molecular Therapy.
- Furey et al. (2024) “Development of a nucleoside-modified mRNA vaccine against clade 2.3.4.4b H5 highly pathogenic avian influenza virus” Nature Communications.
- Wiehe et al. (2024) “Mutation-guided vaccine design: A process for developing boosting immunogens for HIV broadly neutralizing antibody induction” Cell Host & Microbe.
- Acuitas Poster Presentations at ASGCT Annual Meeting
- Nong et al. (2024) “Targeting lipid nanoparticles to the blood-brain barrier to ameliorate acute ischemic stroke” Molecular Therapy.
- Acuitas Therapeutics Named One of Canada’s Top Small & Medium Employers of 2024
- Tafech et al. (2024) “Exploring mechanisms of lipid nanoparticle-mucus interactions in healthy and cystic fibrosis conditions” Advanced Healthcare Materials.
- Tilsed et al. (2024) “IL7 increases targeted lipid nanoparticle–mediated mRNA expression in T cells in vitro and in vivo by enhancing T cell protein translation” PNAS.
- Birdsall et al. (2024) “Monitoring stability indicating impurities and aldehyde content in lipid nanoparticle raw material and formulated drugs” Journal of ChromatographyB.
- Acuitas Therapeutics Named One of BC’s Top Employers of 2024
- Matias et al. (2024) “mRNA vaccination of rabbits alters the fecundity, but not the attachment, of adult Ixodes scapularis” Scientific Reports.
- Kunkeaw et al. (2023) “A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax” NPJ Vaccines.
- Breda et al. (2023) “In vivo hematopoietic stem cell modification by mRNA delivery” Science.
- Hoffmann et al. (2023) “ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines” Cell.
- Gál et al. (2023) “Restoration of motor function through delayed intraspinal delivery of human IL-10-encoding nucleoside-modified mRNA after spinal cord injury” Research.
- Connors et al. (2023) “Lipid nanoparticles (LNP) induce activation and maturation of antigen presenting cells in young and aged individuals” Communications Biology.
- Schiepers et al. (2023) “Molecular fate-mapping of serum antibody responses to repeat immunization” Nature.
- Arevalo et al. (2022) “A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes” Science.
- Gorsuch et al. (2022) “Targeting the Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo” Molecular Therapy.
- Pardi et al. (2022) “Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses” Nature Communications.
- Mu et al. (2022) “mRNA-encoded HIV-1 Env trimer ferritin nanoparticles induce monoclonal antibodies that neutralize heterologous HIV-1 isolates in mice” Cell Reports.
- Rurik et al. (2022) “CAR T cells produced in vivo to treat cardiac injury” Science.
- Mallory et al. (2021) “Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice” NPJ Vaccines.
- Musunuru et al. (2021) “In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates” Nature.
- Rothgangl et al. (2021) “In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels” Nature Biotechnology.
- Rizvi et al. (2021) “Murine liver repair via transient activation of regenerative pathways in hepatocytes using lipid nanoparticle-complexed nucleoside-modified mRNA” Nature Communications.
- Villiger et al. (2021) “In vivo cytidine base editing of hepatocytes without detectable off-target mutations in RNA and DNA” Nature Biomedical Engineering.
- Weissman et al. (2021) “D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization” Cell Host & Microbe.
- Lederer et al. (2020) “SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation” Immunity.
- Laczkó et al. (2020) “A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice” Immunity.
- McKay et al. (2020) “Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice” Nature Communications.
- Freyn et al. (2020) “A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice” Molecular Therapy.
- Raj et al. (2020) “Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria” Nature.
- Marcos-Contreras (2020) “Selective targeting of nanomedicine to inflamed cerebral vasculature to enhance the blood-brain barrier” PNAS.
- Willis et al. (2020) “Nucleoside-modified mRNA vaccination partially overcomes maternal antibody inhibition of de novo immune responses in mice” Science Translational Medicine.
- Huysmans et al. (2019) “Expression kinetics and innate immune response after electroporation and LNP-mediated delivery of a self-amplifying mRNA in the skin” Molecular Therapy Nucleic Acids.
- Pardi et al. (2019) “Characterization of HIV-1 nucleoside-modified mRNA vaccines in rabbits and rhesus macaques” Molecular Therapy Nucleic Acids.
- Conway et al. (2019) “Non-viral delivery of zinc finger nuclease mRNA enables highly efficient in vivo genome editing of multiple therapeutic gene targets” Molecular Therapy.
- Parhiz et al (2018) “PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptake” Journal of Controlled Release.
- Pardi et al. (2018) “Nucleoside-modified mRNA immunization elicits influenza virus hemagglutinin stalk-specific antibodies” Nature Communications.
- Pardi et al. (2018) “Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses” Journal of Experimental Medicine.
- Lutz et al. (2017) “Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines” NPJ Vaccines.
- Thran et al. (2017) “mRNA mediates passive vaccination against infectious agents, toxins, and tumors” EMBO Molecular Medicine.
- Pardi et al. (2017) “Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge” Nature Communications.
- Pardi et al. (2017) “Zika virus protection by a single low-dose nucleoside-modified mRNA Vaccination” Nature.
- Pardi et al. (2015) “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes” Journal of Controlled Release.
- Thess et al. (2015) “Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals” Molecular Therapy.
- Maier et al. (2013) “Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics” Molecular Therapy.
- Mui et al. (2013) “Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles” Molecular Therapy Nucleic Acids.
- Jayaraman et al. (2012) “Maximizing the potency of siRNA lipid nanoparticles for hepatic gene silencing in vivo” Angewandte Chemie.
- Akinc et al. (2010) “Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms” Molecular Therapy.
- Semple et al. (2010) “Rational design of cationic lipids for siRNA delivery” Nature Biotechnology.